The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label, phase III study of mirvetuximab soravtansine versus investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression.
 
Kathleen N. Moore
Honoraria - Prime Oncology; Research To Practice
Consulting or Advisory Role - Abbvie; Aravive; AstraZeneca (Inst); Clovis Oncology; Eisai; Genentech/Roche; Immunogen; Janssen Oncology; Merck; Mersana (Inst); OncoMed; Pfizer/EMD Serono; Samumed; TESARO (Inst); Vavotar Life Sciences; VBL Therapeutics
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
 
Toon Van Gorp
No Relationships to Disclose
 
Jiuzhou Wang
Employment - ImmunoGen
Stock and Other Ownership Interests - ImmunoGen
 
Brooke Esteves
Employment - ImmunoGen
Stock and Other Ownership Interests - Immunogen
 
Patrick A Zweidler-McKay
Employment - Immunogen
Stock and Other Ownership Interests - Immunogen
Patents, Royalties, Other Intellectual Property - Patent applications submitted, no royalties